Farmacosorveglianza degli inibitori selettivi della cicloossigenasi-2: Progetto collaborativo tra i servizi farmaceutici e la medicina generale

Caterina Anecchino; Simona Monte; Rita Salotti; Domenica Costantino; Elisa Sasso; Antonella Di Matteo; Marilena Romero

Farmacosorveglianza degli inibitori selettivi della cicloossigenasi-2: Progetto collaborativo tra i servizi farmaceutici e la medicina generale

Translated title of the contribution: Post-marketing surveillance of cyclooxygenase-2 selective inhibitors: A collaborative study with pharmacists and general practitioners

Caterina Anecchino, Simona Monte, Rita Salotti, Domenica Costantino, Elisa Sasso, Antonella Di Matteo, Marilena Romero

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Over a very short period of time since their marketing authorisation, COXIBs have become more widely used then traditional NSAIDs. The discussion on the real safety/efficacy of this «new» drug category is however still open. A pilot study has been conducted to assess the feasibility of establishing a prospective cohort of patients exposed to COXIBs, through a network of 22 pharmaceutical units of the NHS each recruiting 10 GPs. Over a period of 6 months, 1962 patients have been recruited and monitored for their clinical course according to a predefined post marketing oriented protocol.

Translated title of the contribution	Post-marketing surveillance of cyclooxygenase-2 selective inhibitors: A collaborative study with pharmacists and general practitioners
Original language	Italian
Pages (from-to)	187-192
Number of pages	6
Journal	Giornale Italiano di Farmacia Clinica
Volume	16
Issue number	4
Publication status	Published - Oct 2002

ASJC Scopus subject areas

Pharmacology (medical)

Cite this

@article{a3765332357741b4a96b4c839e387f35,

title = "Farmacosorveglianza degli inibitori selettivi della cicloossigenasi-2: Progetto collaborativo tra i servizi farmaceutici e la medicina generale",

abstract = "Over a very short period of time since their marketing authorisation, COXIBs have become more widely used then traditional NSAIDs. The discussion on the real safety/efficacy of this «new» drug category is however still open. A pilot study has been conducted to assess the feasibility of establishing a prospective cohort of patients exposed to COXIBs, through a network of 22 pharmaceutical units of the NHS each recruiting 10 GPs. Over a period of 6 months, 1962 patients have been recruited and monitored for their clinical course according to a predefined post marketing oriented protocol.",

keywords = "Cyclooxygenase-2 selective inhibitors, General practitioners, Post-marketing surveillance",

author = "Caterina Anecchino and Simona Monte and Rita Salotti and Domenica Costantino and Elisa Sasso and {Di Matteo}, Antonella and Marilena Romero",

year = "2002",

month = oct,

language = "Italian",

volume = "16",

pages = "187--192",

journal = "Giornale Italiano di Farmacia Clinica",

issn = "1120-3749",

publisher = "Il Pensiero Scientifico Editore s.r.l.",

number = "4",

}

TY - JOUR

T1 - Farmacosorveglianza degli inibitori selettivi della cicloossigenasi-2

T2 - Progetto collaborativo tra i servizi farmaceutici e la medicina generale

AU - Anecchino, Caterina

AU - Monte, Simona

AU - Salotti, Rita

AU - Costantino, Domenica

AU - Sasso, Elisa

AU - Di Matteo, Antonella

AU - Romero, Marilena

PY - 2002/10

Y1 - 2002/10

N2 - Over a very short period of time since their marketing authorisation, COXIBs have become more widely used then traditional NSAIDs. The discussion on the real safety/efficacy of this «new» drug category is however still open. A pilot study has been conducted to assess the feasibility of establishing a prospective cohort of patients exposed to COXIBs, through a network of 22 pharmaceutical units of the NHS each recruiting 10 GPs. Over a period of 6 months, 1962 patients have been recruited and monitored for their clinical course according to a predefined post marketing oriented protocol.

AB - Over a very short period of time since their marketing authorisation, COXIBs have become more widely used then traditional NSAIDs. The discussion on the real safety/efficacy of this «new» drug category is however still open. A pilot study has been conducted to assess the feasibility of establishing a prospective cohort of patients exposed to COXIBs, through a network of 22 pharmaceutical units of the NHS each recruiting 10 GPs. Over a period of 6 months, 1962 patients have been recruited and monitored for their clinical course according to a predefined post marketing oriented protocol.

KW - Cyclooxygenase-2 selective inhibitors

KW - General practitioners

KW - Post-marketing surveillance

UR - http://www.scopus.com/inward/record.url?scp=0038249133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038249133&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0038249133

SN - 1120-3749

VL - 16

SP - 187

EP - 192

JO - Giornale Italiano di Farmacia Clinica

JF - Giornale Italiano di Farmacia Clinica

IS - 4

ER -

Farmacosorveglianza degli inibitori selettivi della cicloossigenasi-2: Progetto collaborativo tra i servizi farmaceutici e la medicina generale

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this